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Dear Editor,
Immunogenic cell death (ICD) facilitates danger signalling-
driven trafficking of damage-associated molecular patterns
(DAMPs) like extracellular ATP (eATP).1,2 The binding of eATP
to P2X7 receptor triggers immunogenic signalling,
3 which
(along with other factors) converts the dying cancer cells into
an effective anticancer vaccine.3
Endoplasmic reticulum (ER) stress is central to ICD,1
on the basis of which ICD inducers are subdivided into two
types,1 that is, Type I (e.g., some chemotherapies), which elicit
danger signalling through 'collateral' non-lethal ER
stress,1 and Type II (e.g., hypericin-photodynamic therapy
(Hyp-PDT)), which elicit danger signalling via 'focused' lethal
ER stress.1,4 Type II and Type I ICD inducers differ on several
levels, for example, plasticity of danger signalling and the
trafficking mechanisms of DAMPs.4 In fact, eATP was
found to be absent during Newcastle disease virus
(NDV)-induced Type II ICD despite the induction of macro-
autophagy (a Type I ICD-associated, eATP-trafficking
mechanism).2,5 Moreover, we have established that Hyp-
PDT-induced eATP is PERK and secretory pathway-
dependent,6 while being independent of macroautophagy7
or chaperone-mediated autophagy.8 This raised an important
question – like in the case of NDV-induced ICD, could eATP be
dispensable or a partial immunogenic signal for Hyp-PDT-
induced ICD?
To this end, we decided to gain further insights into the
eATP-trafficking mechanism and its immunogenic potential
following Hyp-PDT. To address the contribution of the
pannexin/connexin-caspase axes2 that elicits eATP
secretion (in response to Type I ICD inducers but remains
enigmatic in the Type II settings), we utilized the pan-pannexin/
connexin inhibitor, carbenoxolone (CBX). In CT26 cells
treated with Hyp-PDT, CBX pretreatment failed to reduce
eATP (Figure 1a), thereby suggesting the dispensability of
pannexins/connexins. Next, we addressed the role of caspase
activity using the pan-inhibitor, zVAD-fmk. Interestingly,
zVAD-fmk significantly reduced Hyp-PDT-induced eATP
(Figure 1a). Considering the previously demonstrated
role of casp-8 in ICD1,6 we wondered whether this
caspase was mediating eATP secretion. Interestingly, CT26
cells expressing caspase-8 shRNA (casp-8 shRNA) also
exhibited significantly reduced eATP following Hyp-PDT
(Figure 1a).
The regulation of eATP secretion by casp-8 was unex-
pected, as our previous study found casp-8 to be
dispensable for Hyp-PDT-induced ICD, in vivo.6 This sug-
gested that eATP secretion may not be crucial for Hyp-PDT-
induced ICD, in vivo. To resolve this, we utilized the CT26-
BALB/c mice prophylactic vaccination model. Immunogenic
effects of eATP were blocked using either Apyrase or Apy
(an ATP-degrading enzyme, Figure 1b) or a 2,3-dialdehyde
derivative of ATP, that is, oxidized-ATP (Oxi-ATP, a P2X7
receptor antagonist) or a combination of both (i.e., Apy+Oxi-
ATP).3 Approximately 70% of the mice immunized with Hyp-
PDT-based vaccine efficiently rejected the formation of CT26
tumours at the challenge site (Figure 1c). Interestingly,
eATP degradation or blockade of P2X7 receptor, alone,
failed to strongly reduce the tumour-rejecting immunity
(Figure 1c). On the other hand, only the combination of
Apy+Oxi-ATP significantly reduced the vaccine's tumour-
rejecting capacity (Figure 1c). Thus, eATP, despite being
ubiquitously secreted after Hyp-PDT,6,7,8 only acts as a partial
immunogenic signal, and thus singular blockade of either
eATPor its P2X7 receptor is unable to reduce the immunogenic
potential of the vaccine.
These results are unprecedented because eATP and
P2X7 receptor had been shown to act in a synergistic
manner.1,2,3 Here, we rather observed a potentiating
effect, that is, blockade of either eATP or P2X7 receptor did
not, but combined blockade significantly reduced ICD's
immunogenic potential. Thus, our results suggest that the
mere presence of eATP does not ensure the presence
of corresponding immunogenic activity in all contexts.
Moreover, a certain degree of redundancy exists on the
level of purinergic receptor agonists, and thus these results
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may also point to the release of such (as-yet-uncharacterized)
agonists from dying cells. Lastly, these observations are
based on the heterotopic (subcutaneous) tumour model; it
would be crucial to reanalyze the role of eATP in an orthotopic
tumour model to overcome immunological variations stem-
ming from incompatibility between the transplanted cancer
type and the surrounding tissue.
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Figure 1 Extracellular ATP and P2X7 receptor together potentiate ICD in cancer. (a) CT26 cells were treated with Hyp-PDT (dosage: 150 nM Hypericin preincubation for
16 h followed by light irradiation with a total fluence of 2.70 J/cm2) as described previously6 and recovered for eATP analysis 1 h post treatment. Depending on the settings (as
indicated in the legends above the graphs), the cells were preincubated with CBX (100 μM for 1 h) or zVAD-fmk (25 μM for 30 min). Alternatively, CT26 cells expressing control
shRNA (CO-shRNA) or casp-8 shRNA were utilized as described previously.6 Extracellular ATP was detected using the standard luciferin-luciferase bioluminescence assay.7
Here, n= 3–4, mean± S.E.M., Student's t-test, **Po0.01 and ***Po0.001, NS, non-significant; CNTR, untreated controls. (b) In another case, CT26 cells were treated with
Hyp-PDT as described above and incubated for 15 min post recovery with Apyrase (Apy; 10 U/ml); eATP was then analyzed as described above. (c) For testing of
immunogenicity, the CT26-BALB/c mice model was utilized.6 Here, the CT26 cells were treated with Hyp-PDT followed by 'vaccine' preparation as described previously.6 In certain
cases, the vaccines were mixed/co-injected with either Apy (10 U/ml for 15 min) or Oxi-ATP (4 mg/kg per mouse) or both (Apy+Oxi-ATP). These respective vaccines were given
twice with an interval of 7–8 days between vaccinations in one of the flanks of the syngenic BALB/c mice. About 8–10 days following the vaccination regimen, the vaccinated mice
were challenged on the contra-lateral flank with live CT26 cells. Thereafter, the mice were monitored for the occurrence of CT26 tumours at the challenge site. Here, n= 10 for
PBS, n= 12 for Hyp-PDT, n= 12 for Hyp-PDT+Apy, n= 12 for Hyp-PDT+Oxi-ATP and n= 6 for Hyp-PDT+Apy+Oxi-ATP, Fisher's exact test; *Po0.05, **Po0.01 and
***Po0.001; NS, non-significant
Correspondence
2
Cell Death and Disease
the Flemish Government. This paper represents research results of the IAP7/32 funded
by the Interuniversity Attraction Poles Programme, initiated by the Belgian State.
1. Garg AD et al. Front Immunol 2015; 6: 588.
2. Martins I et al. Cell Death Differ 2014; 21: 79–91.
3. Ghiringhelli F et al. Nat Med 2009; 15: 1170–1178.
4. Garg AD et al. Cell Death Differ 2014; 21: 26–38.
5. Koks CA et al. Int J Cancer 2015; 136: E313–E325.
6. Garg AD et al. EMBO J 2012; 31: 1062–1079.
7. Garg AD et al. Autophagy 2013; 9: 1292–1307.
8. Garg AD, Dudek AM, Agostinis P. Cell Death Dis 2013; 4: e826.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
Correspondence
3
Cell Death and Disease
